MarketPulse

IND submission

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Cogent Biosciences, Inc.

Cogent Biosciences Showcases Dual Pipeline Advances at AACR 2026 Meeting

Cogent Biosciences highlights preclinical data for KRAS and HER2 inhibitors at AACR 2026, with IND submission planned for CGT1263.
COGTIND submissionAACR Annual Meeting
GlobeNewswire Inc.GlobeNewswire Inc.··Alethio Therapeutics

Alethio Therapeutics Unveils First Mutation-Agnostic Antibody for $2B Essential Thrombocythemia Market

Alethio Therapeutics unveils ATX-011, a first-in-class antibody for treating Essential Thrombocythemia, with IND submission targeted for Q1 2027 and clinical data expected H1 2028.
AZNmonoclonal antibodyclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Curanex Advances Phyto-N Toward Late-Stage Development as Clinical Timeline Solidifies

Curanex advances Phyto-N toward IND submission in Q4 2026, completing manufacturing and toxicology milestones with secured 12-month funding.
CURXclinical trialspharmaceutical development
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Vesicor Therapeutics Appoints Veteran Biotech Executive Tolentino as CEO Ahead of SPAC Merger

Vesicor Therapeutics names Michael Tolentino as CEO effective March 2026, succeeding founder Luo Feng. Leadership transition precedes de-SPAC merger completion and 2027 FDA submission.
BKHABKHARBKHAUSPAC mergerCEO appointment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Editas Medicine Slashes Q4 Losses While Advancing CRISPR Therapy Toward Human Trials

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.
BMYCELGrEDITclinical trialCRISPR